{
    "symbol": "TSHA",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-13 11:25:53",
    "content": " These statements may include the expected timing and results of clinical trials for our product candidates, our expectations regarding the data necessary to support regulatory approval of TSHA-120 and the regulatory status and market opportunity for those programs as well as Taysha's manufacturing plans. Of the patients treated in the efficacy dose onto the study, 42% or 5 of 12 patients had a positive SNAP past the age of 9 years and of the last patient visit, which is remarkable considering that none of the natural history of patients had a positive snap past the age of 9 years. Please proceed with your question. Please proceed with your question. So -- and they've also been a fairly, I guess, a forgotten group and the Rett patient community are actually very pleased that's part of our clinical development program, which, as we alluded to earlier in the call, we're starting in avals initially during the course of 2023, we'll start a pediatric girl study, and then we'll also do a pediatric boys study, a rescue study. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}